Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 14/20 | 0.56 |
| ▸ | KIT | P10721 | 8/20 | 0.56 |
| ▸ | LCK | P06239 | 5/20 | 0.56 |
| ▸ | CSF1R | P07333 | 5/20 | 0.56 |
| ▸ | LYN | P07948 | 5/20 | 0.56 |
| ▸ | SRC | P12931 | 5/20 | 0.56 |
| ▸ | FLT4 | P35916 | 5/20 | 0.56 |
| ▸ | FLT3 | P36888 | 5/20 | 0.56 |
| ▸ | BLK | P51451 | 5/20 | 0.56 |
| ▸ | FYN | P06241 | 4/20 | 0.56 |
| ▸ | FLT1 | P17948 | 4/20 | 0.47 |
| ▸ | CDK19 | Q9BWU1 | 1/20 | 0.47 |
| ▸ | BLM | P54132 | 1/20 | 0.47 |
| ▸ | ABL1 | P00519 | 1/20 | 0.46 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.45 |
| ▸ | PDGFRA | P16234 | 4/20 | 0.45 |
| ▸ | AURKA | O14965 | 1/20 | 0.44 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.44 |
| ▸ | DYRK3 | O43781 | 1/20 | 0.44 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1703153 | 0.89 | KDR (0.57) | KDRKITLCKCSF1RLYN | |
| SCHEMBL1702911 | 0.87 | KDR (0.60) | KDRKITLCKCSF1RFLT4 | |
| SCHEMBL1703125 | 0.86 | KDR (0.60) | KDRKITLCKCSF1RLYN | |
| SCHEMBL1703490 | 0.85 | KIT (0.57) | KDRKITLCKCSF1RLYN | |
| SCHEMBL1703220 | 0.85 | KDR (0.53) | KDRKITLCKCSF1RLYN | |
| SCHEMBL3443154 | 0.84 | CYP3A4 (0.58) | KDRKITLCKCSF1RLYN | |
| SCHEMBL1703595 | 0.84 | CYP3A4 (0.58) | KDRKITLCKCSF1RLYN | |
| SCHEMBL3442461 | 0.84 | CYP3A4 (0.60) | KDRKITLCKCSF1RLYN | |
| SCHEMBL3442391 | 0.83 | KDR (0.56) | KDRKITLCKCSF1RLYN | |
| SCHEMBL1703031 | 0.81 | KDR (0.60) | KDRKITLCKCSF1RLYN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1807424-B1 | NOVEL KINASE INHIBITORS | ABBOTT LAB (US) | 2012-04-18 | — | — | EP | disclosed |
| US-7812166-B2 | Kinase inhibitors | ABBOTT LABORATORIES (US) | 2010-10-12 | — | — | US | disclosed |
| US-20060178378-A1 | Novel kinase inhibitors | ABBVIE INC. | 2006-08-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060178378-A1 | Novel kinase inhibitors | ABL1, MAP3K19, MAP3K20 | KDR 434/4885KIT 426/4885LCK 23/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.